0 CHECKOUT

EpiCast Report: Epilepsy - Epidemiology Forecast to 2022

  • ID: 2418329
  • December 2012
  • 41 Pages
  • GlobalData

EpiCast Report: Epilepsy - Epidemiology Forecast to 2022

Summary

Epilepsy affects 50 million people worldwide each year and is one of the most common neurological conditions in the world (WHO, 2005). Epilepsy is defined as a collection of brain dysfunction disorders characterized by recurrent and unpredictable seizures. The prevalence of epilepsy varies among countries due to a mosaic of economic, political, and social differences. GlobalData epidemiologists expect that the number of active and lifetime prevalent cases of epilepsy will increase during the forecast period (2012–2022) in the nine markets covered. In 2012, we estimated that there was a total of 17,542,651 active prevalent cases of epilepsy in the nine markets, and GlobalData epidemiologists forecast that by 2022, the number of active prevalent cases will grow to 18,565,967. A major strength of this analysis is that the forecast methodology was consistent across the nine markets to allow for a meaningful comparison of the patient populations in each country.

Scope

- The Epilepsy EpiCast Report provide an overview of risk factors and global trends for epilepsy.
- Data is provided for READ MORE >

Note: Product cover images may vary from those shown

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Upcoming Related Reports
3 Epidemiology
3.1 Risk Factors and Comorbidities
3.1.1 Risk factors in newborns often include brain malformations and lack of oxygen
3.1.2 Genetic factors and head trauma are risk factors in adults and children
3.1.3 Common seizure triggers include lack of sleep, stress, and photosensitivity
3.1.4 Epilepsy comorbidities in adults and children include pain disorders
3.1.5 Anxiety and depression are major epilepsy comorbidities
3.1.6 Epilepsy with a known cause can be prevented by the avoidance of head injuries
3.2 Global Trends
3.2.1 United States
3.2.2 5EU Markets (France, Germany, Italy, Spain, and the UK)
3.2.3 Asia
3.3 Forecast Methodology
3.3.1 Sources Used
3.3.2 Forecast Assumptions and Methods
3.3.3 Sources Not Used
3.4 Epidemiologic Forecast
3.4.1 Total Active Prevalent Cases of Epilepsy
3.4.2 Total Lifetime Prevalent Cases of Epilepsy
3.4.3 Age-Specific Total Active Prevalent Cases of Epilepsy
3.4.4 Gender-Specific Total Active Prevalent Cases of Epilepsy
3.4.5 Seizure-Specific Total Active Prevalent Cases of Epilepsy
3.5 Discussion
3.5.1 Conclusion on Epidemiological Trends
3.5.2 Limitations of the Analysis
3.5.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
4.2.4 Global Head of Healthcare
4.3 About Us
4.4 About EpiCast
4.5 Contact Us
4.6 Disclaimer

1.1 List of Tables
Table 1: Nine Markets, Sources for Prevalent Cases of Epilepsy Data
Table 2: Nine Markets, Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022
Table 3: Nine Markets, Total Lifetime Prevalent Cases of Epilepsy, All Ages, Male and Female, Select Years, 2012-2022

1.2 List of Figures
Figure 1: Nine Markets, Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022
Figure 2: Nine Markets, Total Lifetime Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022
Figure 3: Nine Markets, Age-Specific Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, 2012
Figure 4: Nine Markets, Gender-Specific Total Active Prevalent Cases of Epilepsy, All Ages, 2012
Figure 5: Nine Markets, Seizure-Specific Proportions of Epilepsy, All Ages, Male and Female, 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S